Is ATX.AX overvalued or undervalued?

ATX.AX currently has a P/E ratio of -6.29. Relative to the sector average of 41.10, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Amplia Therapeutics Limited stock?

Amplia Therapeutics Limited trades on ASX. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of ATX.AX?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying ATX.AX protect my money against local inflation?

Many investors in Latin America buy international stocks like ATX.AX to protect their purchasing power. Because ATX.AX is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy ATX.AX shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is ATX.AX a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well ATX.AX diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocksATX.AX

Amplia Therapeutics Limited

A$0.11+A$0.00+0.00%

ASX / AUD

Market cap

A$54M

P/E

-6.3

EPS (TTM)

A$-0.01

Dividend yield

0.00%

Beta

-0.40

1Y return

-38.24%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$1M2022

$795,0052023

$3M2024

$2M2025

$02026

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.01Low
Current ratio19.78
Cash ratio16.67
Net margin0.0%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

ATX.AX-6.3
Healthcare sector median41.1
S&P 50022.0

Trades about 115% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.26
Price to book1.36
EPS (TTM)A$-0.01
Payout ratio0%
FCF yield-7.94%

Range & risk

A$0.10A$0.28

Trading in the lower third of its 52-week band

Beta-0.40

Profile

What Amplia Therapeutics Limited actually does

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

CEO

Christopher J. Burns

Employees

Headquarters

Melbourne, VIC

Founded

2013-12-19

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save ATX.AX and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

ATX.AX has a beta of -0.40, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Amplia Therapeutics Limited